Citation

Forster EM, Barber JA, Parker FR, Whinnery JE, Burton RR, Boll P. Aviat. Space Environ. Med. 1994; 65(2): 110-116.

Affiliation

Naval Air Warfare Center, Aircraft Division, Warminster, PA 18974-5000.

Copyright

(Copyright © 1994, Aerospace Medical Association)

DOI

unavailable

PMID

8161320

Abstract

Pyridostigmine Bromide (PB) is used as a pre-exposure antidote for the prevention of potentially lethal effects of certain chemical warfare nerve agents by reversibly inhibiting acetylcholinesterase (AChE). This study was designed to determine whether PB has any deleterious effects on acceleration tolerance (+Gz) or performance. Double-blind placebo trials were conducted to evaluate the effects of PB (90 mg) per day on +Gz tolerances and performance. Three types of exposures were used: 1) gradual onset rate (GOR) exposures of 0.1 G/s; 2) a series of rapid onset rate (ROR) exposures of 6.0 G/s; and 3) a simulated aerial combat maneuver (SACM) of 4.5 to 9.0 +Gz. Performance tasks included the Unified Tri-Service Cognitive Performance Assessment Battery (UTC-PAB). The subjects were not able to correlate their symptoms with PB, placebo, or the acceleration exposure itself. Plasma PB individual levels ranged between 6 and 31 ng/ml and AChE levels of inhibition had a range of 12 to 45%. There were no significant effects on +Gz tolerance or performance related to PB. Based on the results of this study, PB does not significantly alter +Gz tolerance or performance. Therefore, we do not expect aircrew taking prophylactic doses of PB to be adversely affected during aerial combat operations.

Language: en